We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





AACC: Better Quality and Patient-Friendliness Needed in Direct Testing

By LabMedica International staff writers
Posted on 27 Jul 2015
In a new position statement on direct-to-consumer (DTC) laboratory testing, the American Association for Clinical Chemistry (AACC; Washington DC, USA) emphasizes the need for patient-friendly reports and for sufficient transparency about quality of tests and results.

DTC testing allows people to order medical tests directly from a lab, without going through their healthcare provider. More...
Noting the paradigm shift among consumers seeking greater control over their own healthcare, AACC has issued a position statement that emphasizes DTC test results must be accurate and easily understood—an area where laboratory medicine professionals play a vital role.

State laws have limited to physicians the ordering of lab tests, but as people have become more engaged in managing their own healthcare, this model has begun to change. Currently, 37 states and the District of Columbia permit consumers to order some or all of their laboratory tests without involvement of a physician. Individuals can also buy over-the-counter test kits or get laboratory services from non-traditional settings such as retail centers. These DTC lab tests can provide invaluable information to individuals about their health status in a timely and convenient manner. However, many healthcare providers and policymakers are concerned that some of these tests may be of questionable quality and value, or that consumers might not have enough background knowledge to make sound decisions based on their test results.

To enhance patient benefit, AACC urges the Centers for Medicare and Medicaid Services and the US Food and Drug Administration (FDA) to require that DTC testing providers disclose sufficient information about their products and services, enabling consumers to make well-informed decisions. These providers should provide: user-friendly descriptions of risks, benefits, and limitations of all tests offered; clear and understandable reports of test results, with enough information to assist in decision-making; prominent instructions to contact a qualified healthcare provider with any questions or concerns; and a comprehensive, public listing of tests offered and prices charged.

Laboratory medicine professionals are integral to this consumer-driven process. AACC encourages lab professionals to collaborate with federal agencies to inform the public about the costs, benefits, interpretation, and limitations of DTC tests. Likewise, consumers should consult qualified professionals in making decisions about their healthcare.

“DTC laboratory testing is a key element of ongoing efforts to empower people in decisions affecting their healthcare,” said AACC CEO Janet B. Kreizman, “AACC supports expanding consumer access to high-quality DTC testing services, and urges policymakers to ensure that these services have demonstrated clinical validity and utility and make a positive impact on patient outcomes.”

Related Links:

American Association for Clinical Chemistry (AACC)
AACC position statement on direct-to-consumer testing



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Pipette Management Software
VIALINK
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.